Liposomal Bupivacaine (Exparel) in Sarcomas

Status Terminated

Clinical Trial Summary

The purpose of this research is to study a medication called liposomal bupivacaine (EXPAREL®). Study doctors want to see if it is safe, if it can reduce pain after surgery, and the study doctor want to study its use after the removal a soft tissue tumor called a sarcoma

Clinical Trial Description

The hypothesis for this project is that using liposomal bupivacaine will reduce patients' morphine equivalent usage postoperatively while maintaining similar pain scores and lengths of stay when compared to patients that did not receive intraoperative liposomal bupivacaine. Thus, if the use of liposomal bupivacaine proves to aid in pain control and the reduction of initial opiate use following soft tissue sarcoma resection, it could be reasonably suggested that liposomal bupivacaine become incorporated into a multimodal form of pain management following soft tissue sarcoma resection. These results are expected to have a significant positive impact; allowing for a reduction in narcotic pain medication usage and its associated side effects while decreasing health care expenditures. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03867188
Study type	Interventional
Source	Wake Forest University Health Sciences
Contact
Status	Terminated
Phase	Early Phase 1
Start date	January 14, 2019
Completion date	June 11, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02910895` - A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS)	N/A
Recruiting	`NCT05621668` - A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma	Phase 1
Active, not recruiting	`NCT04032964` - Dose Finding Study of L19TNF and Doxorubicin in Patients With STS	Phase 1
Active, not recruiting	`NCT04577014` - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma	Phase 1/Phase 2
Completed	`NCT01650077` - Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria
Withdrawn	`NCT04906876` - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas	Phase 2
Terminated	`NCT02890368` - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides	Phase 1
Terminated	`NCT02628535` - Safety Study of MGD009 in B7-H3-expressing Tumors	Phase 1
Completed	`NCT02204111` - Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma
Withdrawn	`NCT01663090` - Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas	N/A
Completed	`NCT01259375` - Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma	Phase 2
Completed	`NCT01440088` - A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma	Phase 3
Completed	`NCT01106872` - Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas	Phase 1
Recruiting	`NCT00753727` - Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma	Phase 1/Phase 2
Terminated	`NCT00755261` - Phase II Study of Doxorubicin and Avastin® in Sarcoma.	Phase 2
Completed	`NCT00580320` - Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma	Phase 1
Completed	`NCT00611078` - Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study	N/A
Completed	`NCT03452644` - US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors
Recruiting	`NCT05539677` - Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
Terminated	`NCT03520959` - A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)	Phase 3